Crinetics Pharmaceuticals (CRNX) Net Margin (2017 - 2026)

Crinetics Pharmaceuticals' Net Margin history runs 10 years deep, the most recent figure standing at 2322.28% for Q1 2026.

• In Q1 2026, Net Margin fell 2912948.0% year-over-year to 2322.28%; the TTM figure through Mar 2026 stood at 2138.26% (down 390221.0% YoY), while the FY2025 annual figure was 6046.22%, up 2262924.0% from the prior year.
• Net Margin for Q1 2026 stood at 2322.28%, down from 1990.5% in the prior quarter.
• The five-year high for Net Margin was 26807.2% in Q1 2025, with the low at 90972.73% in Q3 2025.
• The 5-year median for Net Margin is 7749.81% (2022), against an average of 1507.36%.
• The sharpest annual moves came in 2022 and 2026: Net Margin soared 2345961 bps in 2022, then tumbled 2912948 bps in 2026.
• Crinetics Pharmaceuticals' Net Margin stood at 6345.7% in 2022, then surged by 157 bps to 16318.21% in 2023, then climbed by 14 bps to 18560.15% in 2024, then sank by 111 bps to 1990.5% in 2025, then slipped by 17 bps to 2322.28% in 2026.
• Business Quant data shows CRNX's Net Margin at 2322.28% in Q1 2026, 1990.5% in Q4 2025, and 90972.73% in Q3 2025.